About Alcon
Alcon is a company based in Fort Worth (United States) founded in 1945 was acquired by Novartis in August 2010. Alcon has raised $171.61 million across 7 funding rounds from investors including HSBC, Nestlé and Novartis. The company has 25,600 employees as of December 31, 2024. Alcon has completed 19 acquisitions, including Aerie Pharma, Aurion Biotech and BELKIN Vision. Alcon offers products and services including Clareon PanOptix Pro and Vision Care Products. Alcon operates in a competitive market with competitors including Sight Sciences, Iantrek, Keranova, Zhitong Technology and Migos Medical, among others.
- Headquarter Fort Worth, United States
- Employees 25600 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alcon Ag
-
Annual Revenue
$9.64 B (USD)2.73as on Dec 31, 2024
-
Net Profit
$989.58 M (USD)2.43as on Dec 31, 2024
-
EBITDA
$2.57 B (USD)7.91as on Dec 31, 2024
-
Total Equity Funding
$171.61 M (USD)
in 7 rounds
-
Latest Funding Round
$2 B (USD), Debt – Conventional
Sep 16, 2019
-
Investors
HSBC
& 2 more
-
Employee Count
25600
as on Dec 31, 2024
-
Investments & Acquisitions
Aerie Pharma
& 18 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alcon
Alcon is a publicly listed company on the SIX with ticker symbol ALC in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alcon
Alcon offers a comprehensive portfolio of products and services, including Clareon PanOptix Pro and Vision Care Products.
Provides advanced vision correction with optimal light utilization.
Offers treatments for eye health and surgical needs.
People of Alcon
Unlock access to complete
Unlock access to complete
Software Development Team
204 people
Leadership Team
148 people
Sales and Marketing
74 people
Senior Team
64 people
Product Management Team
47 people
Human Resources and Administration
41 people
Finance and Accounting
36 people
Legal and Compliance
30 people
Unlock access to complete
Funding Insights of Alcon
Alcon has successfully raised a total of $171.61M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2 billion completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alcon
Alcon has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HSBC, Nestlé and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Universal banking and financial advisory services are provided globally.
|
Locked | Locked | Locked | |
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Locked | Locked | Locked | |
|
Multi-category food and beverage products are produced and distributed globally.
|
Locked | Locked | Locked |
Investor details for Alcon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alcon
Alcon has strategically engaged in corporate development activities, having acquired 19 companies. Notable acquisitions include Aerie Pharma, Aurion Biotech and BELKIN Vision.
Investment portfolio details for Alcon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Aurion Biotech is focused on developing advanced therapies for ocular diseases.
|
Locked | Locked | 2021 | Locked | |
|
Eye drop products are offered via the official EYSUVIS website.
|
Locked | Locked | 2017 | Locked | |
|
Laser device for glaucoma treatment developed by BELKIN Vision.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Alcon
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alcon
Detailed financials for Alcon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alcon Comparisons
Peer comparison for Alcon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alcon
Alcon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sight Sciences, Iantrek, Keranova, Zhitong Technology and Migos Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Surgical systems for ophthalmological disease treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of a minimally invasive eye surgery technology
|
|
| Locked | Locked | Locked |
Surgical equipment for anterior chamber ophthalmic surgery is developed.
|
|
| Locked | Locked | Locked |
Developer of surgical devices for ophthalmic indications
|
|
| Locked | Locked | Locked |
Minimally invasive ophthalmology devices for glaucoma are developed.
|
Detailed competitors of Alcon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alcon
Complete news archive for Alcon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alcon
Alcon was founded in 1945 and raised its 1st funding round 65 years after it was founded.
Alcon is headquartered in Fort Worth, United States. It is registered at Fort Worth, Texas, United States.
David Endicott is the current CEO of Alcon.
Alcon is a funded company, having raised a total of $171.61M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Alcon is 25,600.
Annual revenue of Alcon is $9.64B as on Dec 31, 2024.
Alcon was founded in 1945 and is headquartered in Fort Worth, United States. Operations focus on the medical technology sector, where pharmaceuticals, surgical equipment, and devices are developed, manufactured, and marketed. Contact lens solutions and other vision care products are also produced to address eye diseases, disorders, and conditions. The company serves global markets through these specialized offerings.
Alcon's top competitors include Sight Sciences, Iantrek and Keranova.
Alcon offers Clareon PanOptix Pro and Vision Care Products.
Yes, Alcon is publicly traded on SIX under the ticker symbol ALC.
Alcon has made 19 acquisitions, including Aerie Pharma, Aurion Biotech, and BELKIN Vision.
The ticker symbol of Alcon is ALC on SIX.